Pharma stock jumps 5% after receiving supply contract from Aster Biotech for APIs and specialty chemicalsPharma stock jumps 5% after receiving supply contract from Aster Biotech for APIs and specialty chemicals

Introduction:

Leading pharmaceutical company has secured a multi-year supply contract with a renowned UK-based distribution firm. The agreement involves supplying Active Pharmaceutical Ingredients, intermediates, and specialty chemicals, with an estimated value of ₹182.7 crore for the first year.

Also Read: EMS stock to watch after it receives manufacturing award from Thales

Share price movement of Remedium Lifecare:

On February 17, 2025, Remedium Lifecare Ltd opened at ₹3.97, up 4.75% from its previous close of ₹3.79. The stock hit a high of ₹3.97 (4.75%) and a low of ₹3.87. By 2:45 PM, it traded at ₹3.96, rising 4.49%, with a market cap of ₹160.07 crore.

Remedium Lifecare Secures Multi-Year Supply Contract:

Remedium Lifecare Limited has secured a multi-year supply contract from Aster Biotech Limited, UK. The agreement covers the supply of Active Pharmaceutical Ingredients (APIs), intermediates, and specialty chemicals. The contract, running from February 2025 to January 2028, holds a significant value.

The first year of the contract, from February 2025 to January 2026, is valued at approximately INR 182.7 crore. The agreement establishes Remedium Lifecare as a key supplier to the international pharmaceutical sector, strengthening its position in the global market for APIs and specialty chemicals.

Also Read: How to Trade Like a Pro: 3 Technical Analysis Tools Used by Traders

The supply contract reflects Remedium Lifecare’s expanding role in the pharmaceutical industry. With no related party transactions involved, the contract is set to support the company’s growth trajectory. The partnership with Aster Biotech marks a significant step for Remedium Lifecare in the international market.

Recent news on Remedium Lifecare:

As of January 07, 2025, Remedium Lifecare Ltd secured a massive ₹8,500 crore order from Eli Lilly & Company, boosting its global presence. This milestone is expected to drive a surge in the company’s stock prices, creating significant market buzz.

Stock performance of Remedium Lifecare for Period of 1 week, 6 months and 1 year:

Over the past week, Remedium Lifecare Ltd’s stock has decreased by 3.56%. In the last six months, the stock has fallen by 61%. Over the past year, it has seen a significant decline of 87%, indicating ongoing challenges.

Also Read: PSU stock jumps after signing MoU with National Sugar Institute for bioethanol production

Shareholding pattern of Remedium Lifecare:

Particulars	Dec 2024	Sep 2024	Jun 2024
Promoter	1.10%	1.10%	1.10%
FII	0%	0%	0%
DII	0.00%	0.00%	0.00%
Public	98.90%	98.90%	98.90%

About Remedium Lifecare:

Remedium Lifecare Ltd (BSE: 539561), established in 1988, specializes in trading advanced pharmaceutical intermediates, including API intermediates (KSMs & CRMs), and raw materials for domestic and international pharmaceutical companies.

Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time The securities quoted are exemplary and are not recommendatory.